BioRestorative Therapies, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 09/30/23 | FY 06/30/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $359,700 | $401,000 | $145,800 | — | — |
| Cost of revenue | $23,844 | $28,072 | — | — | — |
| Gross profit | $335,856 | $372,928 | $145,800 | — | — |
| Research and development | $10.1M | $6.7M | $4.0M | — | — |
| Operating expenses | $16.0M | $11.9M | $15.4M | — | — |
| Operating income | -$15.6M | -$11.6M | -$15.2M | — | — |
| Pretax income | -$14.2M | -$9.0M | — | — | — |
| Net income | -$14.2M | -$9.0M | -$10.4M | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $1.5M | $547,890 | $884,377 | — | — |
| Current assets | $3.1M | $11.1M | $11.4M | — | — |
| Total assets | $4.1M | $12.3M | $12.6M | — | — |
| Current liabilities | $3.7M | $3.7M | $2.6M | $3.0M | $10.6M |
| Total liabilities | — | $3.7M | $2.6M | $3.0M | $10.7M |
| Stockholders' equity | $356,744 | $8.5M | $10.0M | $10.8M | $2.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$10.8M | -$8.2M | -$6.4M | — | — |
| Depreciation and amortization | $120,238 | $99,309 | $75,989 | — | — |
| Stock-based compensation | $3.3M | $2.8M | $7.8M | — | — |
| Capital expenditure | $116,069 | $106,189 | $171,043 | — | — |
| Free cash flow | -$10.9M | -$8.3M | -$6.6M | — | — |
| Share repurchases | $0 | — | — | — | — |
Shares outstanding 25.5M · Free float 46.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.